Financials data is unavailable for this security.
View more
Year on year Turnstone Biologics Corp 's revenues fell -73.66% from 73.30m to 19.31m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 30.83m to a larger loss of 55.20m.
| Gross margin | -- |
|---|---|
| Net profit margin | -- |
| Operating margin | -- |
| Return on assets | -98.52% |
|---|---|
| Return on equity | -- |
| Return on investment | -127.31% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Turnstone Biologics Corp fell by 17.20m. Cash Flow from Financing totalled 77.05m or 399.08% of revenues. In addition the company used 66.15m for operations while cash used for investing totalled 28.09m.
| Cash flow per share | -3.34 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.58 |
|---|---|
| Tangible book value per share | 2.58 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.38 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -241.67%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
